ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > simple disclosure

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon Apr 18, 2022 8:32pm

150 Views

Post# 34611895

RE:RE:RE:RE:simple disclosure

Elliott, you have to stop the nonsense for someone who cashed and has posted more than anyone else over the last two weeks.

M101, has called it correctly over the past months, others have been on Biogen and other side kicks, a side distraction. After all these years of Cashman's science with more and more mouse validations it's time to call it ?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market